Neurogene Q3 EPS $(1.05) Beats $(1.36) Estimate

Benzinga · 2d ago
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.36) by 22.79 percent. This is a 6.06 percent decrease over losses of $(0.99) per share from the same period last year.